EUVIMEDScopri EUVIMED
Übersichtsarbeit

FGFR2 in the Development and Progression of Cutaneous Squamous Cell Cancer

Ethan M Kallenberger, Alok Khandelwal, Priyatosh Nath, Shaun A Nguyen, John DiGiovanni iD, Cherie-Ann Nathan

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.23835 ↗

At a glance

Übersichtsarbeit in Molecular Carcinogenesis, 2025. Written by Ethan M Kallenberger and 5 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA. Major MEDLINE topics: Receptor, Fibroblast Growth Factor, Type 2, Skin Neoplasms, Carcinoma, Squamous Cell, Disease Progression. Cited 3 times so far (Crossref); 86 references. Funded by: The authors received no specific funding for this work..

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Cutaneous squamous cell carcinoma (cSCC) is an increasingly common malignancy of the skin and the leading cause of death from skin cancer in adults over the age of 85. Fibroblast growth factor receptor 2 (FGFR2) has been identified as an important effector of signaling pathways that lead to the growth and development of cSCC. In recent years, there have been numerous studies evaluating the role FGFR2 plays in multiple cancers, its contribution to resistance to anticancer therapy, and new drugs that may be used to inhibit FGFR2. This review will provide an overview of our current understanding of FGFR2 and potential mechanisms in which we can target FGFR2 in cSCC. The goals of this review are the following: (1) to highlight our current knowledge of the role of FGFR2 in healthy skin and contrast this with its role in the development of cancer; (2) to further explain the specific molecular mechanisms that FGFR2 uses to promote tumorigenesis; (3) to describe how FGFR2 contributes to more invasive disease; (4) to describe its immunosuppressive effects in skin; and (5) to evaluate its effect on current anticancer therapy and discuss therapies on the horizon to target FGFR2 related malignancy.

Subjects

MeSH terms (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 2Skin NeoplasmsCarcinoma, Squamous CellDisease ProgressionHumansSignal TransductionAnimals

Author keywords

epithelial−mesenchymal transitionimmunosuppressionmetastasistreatment resistance

Substances

Receptor, Fibroblast Growth Factor, Type 2FGFR2 protein, human

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Oto/HNS, Health Sciences Center, Louisiana State University, Shreveport, Louisiana, USA.
  • Department of Pharmacology, University of Texas, Austin, Texas, USA.

ORCID profiles: John DiGiovanni

Funding

  • The authors received no specific funding for this work.

Cite

APA

Kallenberger, E. M., Khandelwal, A., Nath, P., Nguyen, S. A., DiGiovanni, J., & Nathan, C. A. (2025). FGFR2 in the Development and Progression of Cutaneous Squamous Cell Cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23835

Vancouver

Kallenberger EM, Khandelwal A, Nath P, Nguyen SA, DiGiovanni J, Nathan CA. FGFR2 in the Development and Progression of Cutaneous Squamous Cell Cancer. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23835

BibTeX
@article{Kallenberger2025,
  author = {Kallenberger, Ethan M and Khandelwal, Alok and Nath, Priyatosh and Nguyen, Shaun A and DiGiovanni, John and Nathan, Cherie-Ann},
  title = {FGFR2 in the Development and Progression of Cutaneous Squamous Cell Cancer},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.23835}
}
Start for free →